Compare Medtronic PLC (MDT) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Charles Schwab Corporation Common Stock — how do they compare? Medtronic PLC trades at $82.32 (market cap $106.61B), while Charles Schwab Corporation Common Stock trades at $100.45 (market cap $178.33B). The key difference: Charles Schwab Corporation Common Stock is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | SCHW | |
|---|---|---|
Market Cap | $106.61B | $178.33B |
Sector | Health | Financials |
52-Week High | $105.35 | $107.21 |
52-Week Low | $73.75 | $85.35 |
Enterprise Value | $125.36B | — |
Dividend Yield | 3.46% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Charles Schwab (SCHW) trades at $102.01, up 0.44% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $1.43 and revenue growth accelerating to $23.92 billion in 2025. Analyst sentiment remains positive with 58% buy ratings and a $120 consensus price target representing 18% upside potential. Recent news highlights strong trading activity and earnings optimism ahead of Q2 results.
The outlook remains favorable with earnings momentum and operational strength driving potential upside. Key opportunities include continued trading revenue growth and margin expansion, while risks involve interest rate sensitivity and market volatility. The stock's current valuation at 20.19 P/E appears reasonable given the company's profitability and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
